114 related articles for article (PubMed ID: 38149454)
1. TS-2021, a third-generation oncolytic adenovirus that carried Ki67 promoter, TGF-β2 5'UTR, and IL-15 against experimental glioblastoma.
Wang J; Zhang J; Zhang Q; Zhang W; Zhang Q; Jin G; Liu F
J Med Virol; 2024 Jan; 96(1):e29335. PubMed ID: 38149454
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells loaded with Ad5-Ki67/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma.
Wang P; Zhang J; Zhang Q; Liu F
Biomed Pharmacother; 2023 Jan; 157():114035. PubMed ID: 36434955
[TBL] [Abstract][Full Text] [Related]
3. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
4. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
[TBL] [Abstract][Full Text] [Related]
5. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
[TBL] [Abstract][Full Text] [Related]
6. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma.
Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F
Virology; 2023 Oct; 587():109885. PubMed ID: 37738842
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
[TBL] [Abstract][Full Text] [Related]
8. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
Oh E; Hong J; Kwon OJ; Yun CO
Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
[TBL] [Abstract][Full Text] [Related]
9. Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma.
Jia X; Wang L; Feng X; Liu W; Wang X; Li F; Liu X; Yu J; Yu B; Yu X
Nano Lett; 2023 Dec; 23(23):11120-11128. PubMed ID: 38032110
[TBL] [Abstract][Full Text] [Related]
10. TGF-β2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells' invasion.
Zhang C; Zhang X; Xu R; Huang B; Chen AJ; Li C; Wang J; Li XG
J Exp Clin Cancer Res; 2017 Nov; 36(1):162. PubMed ID: 29145888
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.
Zhang Q; Zhang J; Tian Y; Zhu G; Liu S; Liu F
Cell Biosci; 2020; 10():124. PubMed ID: 33133514
[TBL] [Abstract][Full Text] [Related]
12. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
[TBL] [Abstract][Full Text] [Related]
14. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
[TBL] [Abstract][Full Text] [Related]
15. Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell.
Liu J; Fang L; Cheng Q; Li L; Su C; Zhang B; Pei D; Yang J; Li W; Zheng J
Cancer Sci; 2012 Oct; 103(10):1880-8. PubMed ID: 22775978
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
17. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
18. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
19. Increased transforming growth factor-β2 in epidermal growth factor receptor variant III-positive glioblastoma.
Zhang X; Wu A; Fan Y; Wang Y
J Clin Neurosci; 2011 Jun; 18(6):821-6. PubMed ID: 21511480
[TBL] [Abstract][Full Text] [Related]
20. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
